Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 49.3%

Neg 0% Neu 0% Pos 49.3%

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.